Thrust Into A New Fundraising Norm
Source: Life Science Leader
By Matthew Pillar, Editor, BioProcess Online
By the time Randy Schatzman, Ph.D., was the guest on The Business of Biotech podcast, his company, Bolt Biotherapeutics, already had closed a $93 million Series C round of financing in the early months of the COVID pandemic. The CEO had joined Bolt, which focuses on immuno-oncology drug discovery and development, only a year prior.
VIEW THE MAGAZINE ARTICLE!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Life Science Leader? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
This website uses cookies to ensure you get the best experience on our website. Learn more